June Off to a Poor ...
AVANIR Pharmaceuticals (AVNR: NASDAQ)
$2.82 -0.15 | -5.05%
06/01/12 - 04:00 PM ET
Company Balance Sheet
| Sep 2011 | Sep 2010 | Sep 2009 | Sep 2008 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 79.54M | 38.77M | 31.49M | 41.38M |
| Receivables | 2.01M | 580.91K | 0.00 | 0.00 |
| Inventories | 252.24K | 652.63K | 114.10K | 17.00K |
| Other Current Assets | 520.49K | 52.87K | 331.72K | 237.33K |
| Total Current Assets | 84.39M | 40.69M | 32.53M | 43.06M |
| Property, Plant & Equipment, Gross | 3.57M | 2.45M | 2.12M | 2.39M |
| Accumulated Depreciation & Depletion | 1.88M | 2.00M | 1.81M | 1.59M |
| Property, Plant & Equipment, Net | 1.70M | 449.71K | 310.68K | 806.91K |
| Intangibles | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Assets | 3.56M | 1.00M | 1.23M | 2.04M |
| Total Non-Current Assets | 5.26M | 1.45M | 1.54M | 2.85M |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 89.65M | 42.14M | 34.07M | 45.91M |
| Accounts Payable | 3.26M | 2.11M | 1.21M | 451.85K |
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Liabilities | 14.19M | 7.72M | 5.84M | 5.89M |
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Liabilities | 4.12M | 6.41M | 8.28M | 11.02M |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 4.12M | 6.41M | 8.28M | 11.02M |
| Total Liabilities | 18.31M | 14.13M | 14.13M | 16.91M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 71.34M | 28.01M | 19.94M | 29.00M |
| Common Par | 12.54K | 9.60K | 8.31K | 0.00 |
| Additional Paid In Capital | 436.64M | 332.10M | 297.92M | 284.99M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -365.32M | -304.68M | -277.99M | -255.99M |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | 0.00 | 580.91K | 0.00 | 0.00 |
| Total Capitalization | 71.34M | 28.01M | 19.94M | 29.00M |
| Total Equity | 71.34M | 28.01M | 19.94M | 29.00M |
| Total Liabilities & Stock Equity | 89.65M | 42.14M | 34.07M | 45.91M |
| Total Common Shares Outstanding | 125.44M | 95.97M | 83.08M | 78.21M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 119.41M | 87.61M | 78.84M | 58.90M |
| Diluted Weighted Shares Outstanding | 119.41M | 87.61M | 78.84M | 58.90M |
| Number of Employees | 188 | 128 | 20 | 20 |
| Number of Part-Time Employees | 0 | 0 | 0 | 0 |
Portfolios with AVNR
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- Contributor10 Most Shorted Stocks in B...
- Contributor5 Stocks Under-$10 Setting ...
- Contributor5 Biotech Drug-Launch Stock...
- ContributorBreakout Stocks Of The Week...
- UserMy Portfolio
- Contributor6 Heavily Shorted Stocks 04...
- Contributor5 Stocks With the Largest S...
- Usergm401
- Userparvardigar
Latest AVNR Headlines from TheStreet
- Avanir Pharmaceuticals CEO Presents At Bank Of America Merrill Lynch Health Care Conference (Transcript) 05.17.12 | 05:05 pm
- Avanir Pharmaceuticals' Presents At Deutsche Bank Securities Annual Health Care Conference (Transcript) 05.09.12 | 11:05 pm
- Avanir Pharmaceuticals' CEO Discusses F2Q2012 Results - Earnings Call Transcript 05.08.12 | 03:05 pm
- Avanir's CEO Presents At Citi 2012 Global Health Care Conference - Transcript 02.29.12 | 01:02 pm
- AVANIR Pharmaceuticals' CEO Discusses F1Q12 Results - Earnings Call Transcript 02.07.12 | 10:02 pm
- Friday's Top 10 Articles, Videos on TheStreet 01.20.12 | 02:01 pm
- Biotech Stock Mailbag: Celldex, Hep C Bubble, Al Mann Anger 01.20.12 | 05:01 am
- AVANIR Stock Hits New 52-Week Low (AVNR) 12.14.11 | 03:12 pm
- Avanir's CEO Discusses Q4 2011 Results - Earnings Call Transcript 12.12.11 | 11:12 pm
- Biotech Stock Mailbag: 2011 Report Card 11.25.11 | 05:11 am
Press Releases for AVNR
- Avanir Pharmaceuticals To Present At Jefferies 2012 Global Healthcare Conference - PR Newswire 05.29.12 | 08:05 am
- Avanir Pharmaceuticals To Present Data At The American Academy Of Neurology Annual Meeting - PR Newswire 04.17.12 | 08:04 am
- Avanir Pharmaceuticals To Present At BioCentury Future Leaders In The Biotech Industry Conference - PR Newswire 04.10.12 | 08:04 am
- Avanir Pharmaceuticals Announces Appointment Of Rohan Palekar As Chief Commercial Officer - PR Newswire 03.16.12 | 08:03 am
- Avanir Pharmaceuticals To Participate In Two Conferences In March - PR Newswire 03.01.12 | 04:03 pm
- Avanir Pharmaceuticals To Participate In Citi 2012 Global Health Care Conference - PR Newswire 02.21.12 | 09:02 am
- Avanir Pharmaceuticals Announces Publication Of Phase III Study Results Showing Efficacy And Safety Of AVP-923 In The Treatment Of Diabetic Neuropathic Pain - PR Newswire 02.08.12 | 09:02 am
- Avanir Pharmaceuticals Announces Date Of Fiscal 2012 First Quarter Financial Results And Conference Call - PR Newswire 01.30.12 | 08:01 am
- Avanir Pharmaceuticals Announces Date Of Fiscal 2011 Fourth Quarter And Year End Financial Results And Conference Call - PR Newswire 12.06.11 | 08:12 am
- Avanir Pharmaceuticals To Participate In Piper Jaffray Health Care Conference - PR Newswire 11.22.11 | 08:11 am
Partner Headlines for AVNR
- Stocks To Watch: Week Of March 19-23 - Seeking Alpha 03.21.12 | 08:03 am
- Avanir Pharmaceuticals: Limelight On The Horizon - Seeking Alpha 02.17.12 | 06:02 am
- Canaccord Reiterates Buy, $6 PT on Avanir Pharmaceuticals - Benzinga 11.30.11 | 09:11 am
- Avanir - Closing Short Position - Seeking Alpha 11.27.11 | 08:11 am
- 10 Small-Cap Stocks Deeply Undervalued By Target Price - Seeking Alpha 11.11.11 | 10:11 pm
- Avanir Pain Drug Should Provide Long-Term Growth - Seeking Alpha 09.30.11 | 06:09 pm
- Avanir: Congressional Inquiry Into the Pricing of Nuedexta Abandoned - Seeking Alpha 07.22.11 | 09:07 am
- Hearing Negative Chatter in Avanir Pharmaceuticals - Benzinga 06.30.11 | 01:06 pm
- Jefferies' Upadates - Benzinga 06.03.11 | 09:06 am
- Investors Should Take Notice of Congressional Questions Regarding Nuedexta Pricing - Seeking Alpha 05.27.11 | 09:05 am





